BDBenan Dernek

Benan Dernek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Benan Dernek has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Targeted Analysis of Spliceosomal snRNA Genes in Unexplained Neurodevelopmental Disorders Identifies ReNU Syndrome and RNU4atac-opathy

    by Benan Dernek, Turkan Turkut Tan, Yusuf Can Dogan, Zehra Burcu Yilmaz, Mehmet Mert Topaloglu, Sanem Keskin Yilmaz, Ozgur Cogulu, Tahir Atik, Esra Isik

    Background and Objectives: Pathogenic variants in genes encoding spliceosomal small nuclear RNAs (snRNAs) have recently emerged as a frequent cause of neurodevelopmental disorders (NDDs), yet these non-coding genes are commonly missed by standard diagnostic pipelines.,Methods: We investigated the diagnostic contribution of targeted snRNA gene analysis in 102 patients with global developmental delay and/or intellectual disability (GDD/ID) who remained undiagnosed after karyotyping, chromosomal microarray, and exome sequencing at a single tertiary pediatric genetics center. Existing exome data were re-evaluated for RNU2-2, RNU4-2, RNU5A-1, RNU5B-1, and RNU4ATAC, and targeted deep amplicon sequencing achieving 100% coverage at >1000× depth was performed where these loci were not captured; candidate variants were confirmed and segregated by Sanger sequencing.,Results: Rare variants were identified in eight patients (7.8%), and a definitive molecular diagnosis was established in three (2.9%). One patient carried the recurrent de novo RNU4-2 n.64_65insT variant and displayed the characteristic ReNU syndrome phenotype, including microcephaly, growth failure, distinctive facial features, and corpus callosum thinning. Two patients harbored biallelic pathogenic RNU4ATAC variants: a homozygous n.16G>A variant associated with a Roifman syndrome phenotype with transient infantile hypogammaglobulinemia, and compound heterozygous n.51G>A and n.111G>A variants in an adult with severe microcephaly, a molar tooth sign consistent with a Joubert-like ciliopathy phenotype, and relapsed Hodgkin lymphoma, an association not previously highlighted in RNU4atac-opathy.,Discussion: Our findings independently replicate the diagnostic relevance of snRNA genes in an unselected, consanguinity-enriched cohort and support incorporating these loci into routine diagnostic algorithms for unexplained NDD.

  • Open Access

    CMV Infection in Pediatric Liver Transplantation and Comparison of Prophylaxis Methods Depending on Donor Serostatus

    by Barut Dogan, Kunay Bora, Yildirim Arslan Sema, Umman Veysel, Dernek Benan, Kıran Taşçı Ezgi, Akkus Kayali Gozde, Sahbudak Bal, Aydogdu Sema, Cetin Funda, et al.

    Background/Aims: Cytomegalovirus (CMV) infection is a significant complication in pediatric liver transplant recipients. This study aimed to assess the incidence, risk factors, and suspected effects of CMV infection in children undergoing liver transplantation and compared acyclovir and ganciclovir-based preventive therapy. Materials and Methods: The study included 92 patients who had liver transplants at Ege University Transplantation Unit between 2011 and 2021. Sixty-four pediatric patients with preoperative CMV immunoglobulin G (IgG) positivity were analyzed. Patients with early mortality, re-transplantation within 6 months, and CMV IgG negativity were excluded. Results: The study consisted of 39 females (61%) and 25 males (39%), with a median age of 5.3 years at transplantation. Cytomegalovirus viremia occurred in 42 patients (65%), and CMV disease developed in 7 patients (10%). The median duration of CMV viremia was 40 days, and CMV disease was 105 days. Age was significantly associated with CMV disease development, with younger patients at higher risk (P = .007). The choice of antiviral treatment (acyclovir vs. valganciclovir) did not significantly impact the development of CMV vire mia or disease. Conclusion: Cytomegalovirus viremia and disease are common in pediatric liver transplant recipients, with younger age being a signifi cant risk factor for CMV disease. However, CMV viremia and disease did not significantly impact this cohort’s graft loss, acute cellular rejection, or mortality. The choice of antiviral treatment and immunosuppression protocols did not influence CMV outcomes. These find ings highlight the need for vigilant monitoring and tailored management strategies for CMV in pediatric liver transplantation. Cite this article as: Dogan B, Bora K, Sema YA, et al. CMV infection in pediatric liver transplantation and comparison of prophylaxis methods depending on donor serostatus. Turk J Gastroenterol. Published online November 7, 2025. doi:10.5152/tjg.2025.24585.